



Billing Code 4410-09-M

DEPARTMENT OF JUSTICE  
DRUG ENFORCEMENT ADMINISTRATION  
MANUFACTURER OF CONTROLLED SUBSTANCES  
NOTICE OF REGISTRATION  
HALO PHARMACEUTICAL INC.

By Notice dated December 2, 2011, and published in the  
Federal Register on December 14, 2011, 76 FR 77850, Halo  
Pharmaceutical Inc., 30 North Jefferson Road, Whippany, New  
Jersey 07981, made application by renewal to the Drug  
Enforcement Administration (DEA) to be registered as a bulk  
manufacturer of the following basic classes of controlled  
substances:

Drug	Schedule
Dihydromorphine (9145)	I
Hydromorphone (9150)	II

Dihydromorphine is an intermediate in the manufacture  
of Hydromorphone and is not for commercial distribution.  
The company plans to manufacture Hydromorphone HCL for sale  
to other manufacturers and for the manufacture of other

controlled substance dosage units for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 USC § 823(a) and determined that the registration of Halo Pharmaceutical Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Halo Pharmaceutical Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 USC § 823(a), and in accordance with 21 CFR § 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Joseph T. Rannazzisi  
Deputy Assistant Administrator  
Office of Diversion Control  
Drug Enforcement Administration

DATED: March 8, 2012

[FR Doc. 2012-6696 Filed 03/19/2012 at 8:45 am; Publication  
Date: 03/20/2012]